ClinicalTrials.gg
CompletedNCT04446377Updated Aug 8, 2023Results posted

A Study of LAM-002A for the Prevention of Progression of COVID-19

A Phase 2 interventional study of Apilimod Dimesylate Capsule and Placebo in COVID-19 Disease, sponsored by OrphAI Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-08.

Sponsored by OrphAI Therapeutics · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
142
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,860 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Enrollment
548th of 1,322
142 · median 92
Started
2020
with 817 others
Phase 2
350 of 1,860
15 open now
Registered
478th of 1,860
by date

Among the 1,860 studies in COVID-19 with a site in United States, this one is the 548th largest by enrollment of the 1,322 interventional ones that give a count, is one of 818 that started in 2020, is one of 350 in phase 2, and was the 478th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,860 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,860 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

This is a clinical trial to evaluate the efficacy of LAM-002A compared to placebo treatment in adults with a confirmed SARS-CoV-2 infection who are receiving standards supportive care in an outpatient setting.

Read the detailed description

This is a Phase II randomized, double-blind, placebo-controlled, clinical study to evaluate the efficacy of LAM-002A compared to placebo treatment in adults with a confirmed SARS-CoV-2 infection who are receiving standard supportive care in an outpatient setting.

Study eligibility will be assessed during screening. All study participants must sign a written informed consent and satisfy the inclusion and exclusion criteria for the study. Confirmation of SARS-CoV-2 infection, medical history, and current medication will be assessed for each consenting participant at screening.

Study participants will be randomized in a 1:1 ratio, to receive study therapy (either LAM-002A, 125 mg [5 capsules/dose]) PO BID or placebo [5 capsules/dose] PO BID) for 10 days. Participants who experience an adverse event (AE) considered to be related to study therapy may have a decrease in study dose of LAM-002A to 100 mg [4 capsules/dose]) PO BID or placebo [4 capsules/dose] PO BID). After the start of treatment on Day 1, participants will be followed at Days 4,6,8,11,22, and 28. Days 6,8, and 22 will be phone visits. Participants can withdraw from the study therapy or study participation at any time.

The study will incorporate an interim safety analysis after the first 30 participants (15 on LAM-002A and 15 on placebo) have completed treatment and have been followed up for 11 days post-first dose. Recruitment and randomization will continue while this analysis is conducted. Recommendations from an independent Data Safety Monitoring Board (DSMB) will be used for decisions of early termination or study design adaptations.

Non-parametric and parametric statistical analysis will be conducted, as appropriate. For the comparison of the LAM-002A active arm and the control arm for the primary endpoint and secondary endpoints of drug effect, appropriate methods will be employed. Baseline subject characteristics, study therapy administration/compliance, safety, supportive care administration, and pharmacokinetics will be analyzed descriptively.

03

Conditions studied

  • COVID-19 Disease

Keywords

  • COVID-19
  • SARS-CoV-2
  • Apilimod Dimesylate
  • LAM-002A
  • Coronavirus
  • AI Therapeutics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written documentation of SARS-CoV-2 infection confirmed by a validated test.
  2. Presence of greater than or equal to ≥1 of the following COVID-19-related symptoms indicating mild disease: fever (temperature ≥100.4), anosmia (loss of taste or smell), cough, sore throat, gastrointestinal complaints (e.g. nausea, vomiting, or diarrhea), chills, congestion, or runny nose, headaches, muscle or body aches, fatigue, or asymptomatic patients who have tested positive for COVID-19 via a validated test within the past 4 days.
  3. If symptomatic, symptom onset less than or equal to ≤ 8 days.
  4. For female participants of , a negative urine (or serum) pregnancy test.
  5. For female participants of childbearing potential, willingness to use a protocol-recommended method of from the start of the screening period until greater than or equal to ≥30 days after the final dose of study therapy. Note: A female subject is considered to be of childbearing potential unless she has had a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy; has medically documented ovarian failure (with serum estradiol and follicle-stimulating hormone [FSH] levels within the institutional laboratory range and a negative serum or urine beta human chorionic gonadotropin [βHCG]); or is menopausal (age ≥50 years with amenorrhea for ≥6 months).
  6. For male participants who can father a child and are having intercourse with females of childbearing potential who are not using adequate contraception, willingness to use a protocol-recommended method of contraception from the start of study therapy until ≥30 days after the final dose of study therapy and to refrain from sperm donation from the start of study therapy until ≥90 days after administration of the final dose of study therapy. Note: A male subject is considered able to father a child unless he has had a bilateral vasectomy with documented aspermia or a bilateral orchiectomy.
  7. Willingness and ability of the participant to ingest study drug capsules.
  8. Willingness of the participant to comply with scheduled visits, drug administration plan, protocol-specified laboratory tests, study procedures, and study restrictions.
  9. Evidence of a personally signed indicating that the participant is aware of the nature of the disease and has been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential risks and discomforts, potential benefits, and other pertinent aspects of study participation.

Exclusion criteria

Exclusion Criteria:

  1. Respiratory rate greater than or equal to ≥20 breaths per minute.
  2. Oxygen saturation by pulse oximetry less than or equal to ≤93 percent % on room air or requirement for supplemental oxygen to maintain oxygen saturation greater than >93 percent %.
  3. Total NEWS score greater than or equal to ≥6 or presence of a score of 3 on any of the individual NEWS parameters.
  4. Radiographic evidence of pulmonary infiltrates (clinical X-ray within 2 days of referral)
  5. Hepatic profile showing any of the following:

    • Serum (ALT) greater than >5 × (ULN) ( Grade greater than or equal to ≥3).
    • Serum aspartate aminotransferase (AST) greater than >5 × ULN (CTCAE Grade greater than or equal to ≥3).
    • Serum greater than >1.5 × ULN (CTCAE Grade greater than or equal to ≥2).
  6. Renal profile showing an estimated (eClCR) less than \<30 mL/minute (with eClCR to be calculated by the method at the laboratory performing the serum creatinine test).
  7. Presence of a cancer with disease manifestations or therapy that could adversely affect subject safety or longevity, create the potential for drug-drug interactions, or compromise the interpretation of study results.
  8. Significant cardiovascular disease (e.g. myocardial infarction, arterial thromboembolism, cerebrovascular thromboembolism) within 1 month prior to start of study therapy; unstable angina; symptomatic peripheral vascular disease; CTCAE Grade greater than or equal to ≥2 congestive heart failure; or uncontrolled CTCAE Grade greater than or equal to ≥3 hypertension (diastolic blood pressure greater than or equal to ≥100 mmHg or systolic blood pressure greater than or equal to ≥160 mmHg) despite antihypertensive therapy.
  9. Significant screening abnormalities, including atrial fibrillation/flutter, 2nd degree atrioventricular (AV) block type II, 3rd-degree AV block, Grade greater than or equal to ≥2 bradycardia, or (QTc by Fridericia [QTcF]) greater than >480 msec (Grade greater than >1).
  10. Gastrointestinal disease (e.g. gastric or intestinal bypass surgery, pancreatic enzyme insufficiency, malabsorption syndrome, symptomatic inflammatory bowel disease, chronic diarrheal illness, bowel obstruction) that might interfere with drug absorption or with interpretation of gastrointestinal AEs.
  11. Pregnancy or breastfeeding.
  12. Prior solid organ transplantation.
  13. Use within 5 days prior to randomization of an approved or therapy intended to treat COVID-19 (e.g. remdesivir, , anti-interleukin [IL]-6 antibodies, therapeutic anti-SARS CoV-2 antibodies or post-convalescent plasma, anti- SARS CoV-2 vaccine, Bruton tyrosine kinase [BTK] inhibitor), use within 3 months of chloroquine or hydroxychloroquine. Note: participants are not precluded from undergoing evaluations involving observation, noninvasive diagnostic procedures or sampling, or questionnaires as follow-up to a prior study or as components of a concurrent noninterventional study.
  14. Use within 5 days prior to randomization of a strong inhibitor or inducer of cytochrome P450 (CYP) 3A4 or expected requirement for chronic use of a strong inhibitor or inducer of during study therapy.
  15. Use within 5 days prior to randomization of drug that is a moderate-to-strong substrate of CYP2C9 (including warfarin, tolbutamide, phenytoin, glimepiride) or expected requirement for chronic use of such drugs during study therapy.
  16. Use within 5 days prior to randomization of a drug known to prolong the QT interval
  17. Ongoing therapy including systemic or enteric . (Note: At study entry, participants may be using intraarticular, inhaled, or topical corticosteroids. During study therapy, participants may use systemic, enteric, intraarticular, inhaled, or topical corticosteroids as required for intercurrent conditions.)
  18. Any illness, medical condition, organ system dysfunction, or social situation, including mental illness or substance abuse, deemed by the investigator to be likely to interfere with a participant's ability to provide , adversely affect the participant's ability to cooperate and participate in the study, or compromise the interpretation of study results.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
142 participants (actual)

Study arms

  • Experimental
    LAM-002A

    LAM-002A (Apilimod Dimesylate) 125mg in five 25-mg capsules BID for 10 days

    Drug: Apilimod Dimesylate Capsule

  • Placebo comparator
    Placebo

    (microcrystalline cellulose) in 5 capsules BID for 10 days

    Other: Placebo

Interventions

  • LAM-002A is formulated in capsules containing 25 mg of apilimod dimesylate. The capsule is Swedish orange, Size 0.

  • OtherPlacebo

    Microcrystalline cellulose in Swedish orange, Size 0 capsules

06

What researchers measure

Primary outcomes

  1. Viral Load Change

    The primary efficacy outcome measure evaluated change in SARS-CoV-2 viral load at Day 4 from Day 1, of LAM-002A or placebo-treated participants. SARS-CoV-2 viral load was measured by a real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) test of nasopharyngeal samples. Analysis focused on log10 viral load on Day 4 compared to baseline viral load at Day 1 in participants with baseline viral load \>100,000 copies/mL

    Time frame: 4 Days

Secondary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    The number and percentage of LAM 002A-treated participants who developed TEAEs compared to placebo

    Time frame: 28 Days

  2. Clinical Efficacy

    Number of Participants with Hospitalization or Death within 28 days

    Time frame: 28 Days

  3. Change in COVID-19 Clinical Status

    To evaluate change in COVID-19 clinical status, as defined by the ordinal scale, of participants treated with LAM-002A compared to placebo at Day 28, in participants who became hospitalized and continued LAM-002A/placebo treatment, based on the following scores: 1. Not in the hospital 2. Hospitalized, requiring low flow supplemental oxygen (such as nasal cannula) 3. Hospitalized, not on invasive ventilation (such as 100% non-rebreather, BIPAP), (pre-ICU) 4. Hospitalized, in the ICU, on invasive ventilation or Extracorporeal membrane oxygenation (ECMO) 5. Dead

    Time frame: 28 Days

  4. Oxygen Saturation

    Comparison of the number and percentage of participants with an oxygen saturation (O2 sat) ≥95% between LAM-002A versus placebo treatment groups.

    Time frame: Baseline, Day 1, Day 4, Day 11, Day28

Other outcomes

  1. Number and Percentage of Participants With Viral Load < Lower Limit of Quantification (LLOQ)

    Evaluated the difference in the number and percentage of participants with a SARS-CoV-2 viral load \<LLOQ between the LAM-002A and the placebo arm as measured by a qRT-PCR test from nasopharyngeal samples at Day 4.

    Time frame: 4 Days

07

Results

Posted Aug 8, 2023
Limitations and caveats
The study was potentially limited in its ability to discern a benefit of LAM-002A on viral and clinical endpoints due to the number of participants enrolled, the low baseline viral loads, and the short (4-day) duration of viral load evaluation.

Participant flow

This study was conducted by 8 investigators located at medical centers throughout the United States

Participant flow — Overall Study
MilestoneLAM-002APlacebo
Started7171
Completed6466
Not completed75
Withdrew: Withdrawal by subject61
Withdrew: Physician decision11
Withdrew: Lost to follow-up02
Withdrew: Not eligible01

Outcome measures

PrimaryViral Load Change

The primary efficacy outcome measure evaluated change in SARS-CoV-2 viral load at Day 4 from Day 1, of LAM-002A or placebo-treated participants. SARS-CoV-2 viral load was measured by a real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) test of nasopharyngeal samples. Analysis focused on log10 viral load on Day 4 compared to baseline viral load at Day 1 in participants with baseline viral load \>100,000 copies/mL

Time frame:
4 Days
Reported as:
Mean · log10 copies/mL
Viral Load Change
log10 copies/mLLAM-002APlacebo
Viral Load Change-2.50 ± 2.35-1.99 ± 1.71
Statistical analysis
  • LAM-002A vs Placebo · Mixed Models Analysis · p = 0.35 (Pre-specified 2-sided significance level of 0.20) · Mean difference (final values): -0.47 · 95% CI -1.47 to 0.53The difference between the groups (LAM-002A vs Placebo).
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

The number and percentage of LAM 002A-treated participants who developed TEAEs compared to placebo

Time frame:
28 Days
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsLAM-002APlacebo
Number of Participants With Treatment-emergent Adverse Events (TEAEs)2614
SecondaryClinical Efficacy

Number of Participants with Hospitalization or Death within 28 days

Time frame:
28 Days
Reported as:
Count of participants · Participants
Clinical Efficacy
ParticipantsLAM-002APlacebo
Yes21
No6970
Statistical analysis
  • LAM-002A vs Placebo · Log Rank · p = 0.55 · Odds ratio (or): 2.03 · 95% CI 0.18 to 22.89
SecondaryChange in COVID-19 Clinical Status

To evaluate change in COVID-19 clinical status, as defined by the ordinal scale, of participants treated with LAM-002A compared to placebo at Day 28, in participants who became hospitalized and continued LAM-002A/placebo treatment, based on the following scores: 1. Not in the hospital 2. Hospitalized, requiring low flow supplemental oxygen (such as nasal cannula) 3. Hospitalized, not on invasive ventilation (such as 100% non-rebreather, BIPAP), (pre-ICU) 4. Hospitalized, in the ICU, on invasive ventilation or Extracorporeal membrane oxygenation (ECMO) 5. Dead

Time frame:
28 Days
Reported as:
Count of participants · Participants
Change in COVID-19 Clinical Status
ParticipantsLAM-002APlacebo
1: Not in the hospital6466
2: Hospitalized, requiring low flow supplemental oxygen (such as nasal cannula)00
3: Hospitalized, not on invasive ventilation (such as 100% non-rebreather, BIPAP), (pre-ICU)00
4: Hospitalized, in the ICU, on invasive ventilation or ECMO00
5: Dead00
Status Unknown*75
SecondaryOxygen Saturation

Comparison of the number and percentage of participants with an oxygen saturation (O2 sat) ≥95% between LAM-002A versus placebo treatment groups.

Time frame:
Baseline, Day 1, Day 4, Day 11, Day28
Reported as:
Count of participants · Participants
Oxygen Saturation
ParticipantsLAM-002APlacebo
Baseline, oxygen saturation ≥95% — Yes6768
Baseline, oxygen saturation ≥95% — No43
Day 1, oxygen saturation ≥95% — Yes6059
Day 1, oxygen saturation ≥95% — No22
Day 4, oxygen saturation ≥95% — Yes5965
Day 4, oxygen saturation ≥95% — No93
Day 11, oxygen saturation ≥95% — Yes6065
Day 11, oxygen saturation ≥95% — No42
Day 28, oxygen saturation ≥95% — Yes6566
Day 28, oxygen saturation ≥95% — No00
Statistical analysis
  • LAM-002A vs Placebo · Risk difference (rd): -1.4
  • LAM-002A vs Placebo · Risk difference (rd): -1.0
  • LAM-002A vs Placebo · Risk difference (rd): -8.8
  • LAM-002A vs Placebo · Risk difference (rd): -3.7
Other pre-specifiedNumber and Percentage of Participants With Viral Load < Lower Limit of Quantification (LLOQ)

Evaluated the difference in the number and percentage of participants with a SARS-CoV-2 viral load \<LLOQ between the LAM-002A and the placebo arm as measured by a qRT-PCR test from nasopharyngeal samples at Day 4.

Time frame:
4 Days
Reported as:
Count of participants · Participants
Number and Percentage of Participants With Viral Load < Lower Limit of Quantification (LLOQ)
ParticipantsLAM-002APlacebo
Number and Percentage of Participants With Viral Load < Lower Limit of Quantification (LLOQ)93
Statistical analysis
  • LAM-002A vs Placebo · Fisher Exact · p = 0.20 (Prespecified significance level of 0.20.) · Relative risk: 2.51 · 95% CI 0.74 to 8.48

Adverse events

Collected over Adverse events were collected from the first administration of study drug through Day 28 or when any ongoing drug-related adverse events (AEs) and/or serious adverse events (SAEs) resolved or became stable, up to 30 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LAM-002A1/71 (1.4%)2/71 (2.8%)26/71 (36.6%)
Placebo0/70 (0%)1/70 (1.4%)15/70 (21.4%)
Most frequent serious events
Most frequent serious events
EventLAM-002APlacebo
DyspnoeaRespiratory, thoracic and mediastinal disorders1/711/70
COVID-19 pneumoniaInfections and infestations1/710/70
Most frequent other events
Showing 10 of 46
Most frequent other events
EventLAM-002APlacebo
DiarrhoeaGastrointestinal disorders7/715/70
NauseaGastrointestinal disorders7/713/70
VomitingGastrointestinal disorders4/712/70
DizzinessNervous system disorders3/710/70
AstheniaGeneral disorders0/712/70
PyrexiaGeneral disorders0/712/70
Feeling abnormalGeneral disorders2/711/70
SinusitisInfections and infestations2/710/70
HeadacheNervous system disorders2/711/70
LethargyNervous system disorders2/710/70

Baseline characteristics

The intention-to-treat (ITT) population included all participants randomized according to their initial randomized assignment regardless of the treatment actually received.

Age, Continuous
Age, Continuous(years)LAM-002APlaceboTotal
Median42.8 (18.7 to 70.4)43.3 (18.5 to 65.7)43.1 (18.5 to 70.4)
Sex: Female, Male
Sex: Female, Male(Participants)LAM-002APlaceboTotal
Female373774
Male343468
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)LAM-002APlaceboTotal
Hispanic or Latino252752
Not Hispanic or Latino454489
Unknown or Not Reported101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)LAM-002APlaceboTotal
Patient Race — White6461125
Patient Race — Black or African American279
Patient Race — Asian303
Patient Race — Other011
Patient Race — Unknown224
Region of Enrollment
Region of Enrollment(participants)LAM-002APlaceboTotal
United States7171142
ECOG Performance Status
ECOG Performance Status(Participants)LAM-002APlaceboTotal
0: Fully active5559114
1: Restricted161127
2: Ambulatory011
Oxygen Saturation
Oxygen Saturation(percent)LAM-002APlaceboTotal
Median98.0 (95.0 to 100.0)98.0 (95.0 to 100.0)98.0 (95.0 to 100.0)
Temperature
Temperature(degrees Celsius)LAM-002APlaceboTotal
Median36.8 (35.7 to 38.6)36.8 (35.6 to 38.0)36.8 (35.6 to 38.6)
08

Study locations

1 site
  • Yale University
    New Haven, Connecticut 06510, United States
09

References and documents

Publications

  • Kumar P, Mathayan M, Smieszek SP, Przychodzen BP, Koprivica V, Birznieks G, Polymeropoulos MH, Prabhakar BS. Identification of potential COVID-19 treatment compounds which inhibit SARS Cov2 prototypic, Delta and Omicron variant infection. Virology. 2022 Jul;572:64-71. doi: 10.1016/j.virol.2022.05.004. Epub 2022 May 16. PubMed 35598394 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Mar 2021, 8 months.

Results were first posted in Aug 2023, 2 years 4 months after primary completion.

Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 8 months is close to that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2020
First posted
Jun 24, 2020
StartActual
Jul 15, 2020
Primary completionActual
Mar 24, 2021
CompletionActual
Apr 19, 2021
Results first posted
Aug 8, 2023
Last update
Aug 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04446377
Lead sponsor
OrphAI Therapeutics
Collaborators
Yale University
Responsible party
Sponsor
First posted
Jun 24, 2020
Start date
Jul 15, 2020
Primary completion
Mar 24, 2021
Completion
Apr 19, 2021
Results posted
Aug 8, 2023
Last update
Aug 8, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apilimod Dimesylate Capsule

Start the discussion